+

WO1997004748A3 - Enveloppes virales artificielles renforcees pour l'apport de substances therapeutiques dans les cellules - Google Patents

Enveloppes virales artificielles renforcees pour l'apport de substances therapeutiques dans les cellules Download PDF

Info

Publication number
WO1997004748A3
WO1997004748A3 PCT/US1996/012750 US9612750W WO9704748A3 WO 1997004748 A3 WO1997004748 A3 WO 1997004748A3 US 9612750 W US9612750 W US 9612750W WO 9704748 A3 WO9704748 A3 WO 9704748A3
Authority
WO
WIPO (PCT)
Prior art keywords
vesicles
therapeutic substances
artificial viral
envelopes
nucleic acid
Prior art date
Application number
PCT/US1996/012750
Other languages
English (en)
Other versions
WO1997004748A9 (fr
WO1997004748A2 (fr
WO1997004748B1 (fr
Inventor
Jon T Conary
Hans Schreier
Original Assignee
Advanced Therapies Inc
Jon T Conary
Hans Schreier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Therapies Inc, Jon T Conary, Hans Schreier filed Critical Advanced Therapies Inc
Priority to AU66914/96A priority Critical patent/AU6691496A/en
Publication of WO1997004748A2 publication Critical patent/WO1997004748A2/fr
Publication of WO1997004748A3 publication Critical patent/WO1997004748A3/fr
Publication of WO1997004748B1 publication Critical patent/WO1997004748B1/fr
Publication of WO1997004748A9 publication Critical patent/WO1997004748A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des enveloppes virales artificielles et d'autres vésicules lipidiques qui encapsulent des substances thérapeutiques telles que des vecteurs d'expression visant des cellules de mammifères. Les polynucléotides peuvent être mis dans les enveloppes par compression à l'avance avec un peptide court ayant une charge positive prédominante. L'opération de compression non seulement facilite l'encapsulation mais elle augmente aussi le nombre de vésicules contenant de l'acide nucléique, réduit au minimum la quantité d'acide nucléique libre, et elle peut aussi augmenter la taille et la complexité des plasmides qui peuvent être encapsulés. Les vésicules peuvent être pourvues d'un constituant ciblant des tissus, qui aide à les diriger vers certains sites tissulaires d'un animal, et elles peuvent aussi être pourvues d'un constituant fusogénique qui facilite l'apport de la substance thérapeutique dans la cellule. Les substances et les réactifs selon la présente invention sont efficaces, par exemple, pour accroître l'expression de protéines modèles à la fois dans des cellules isolées et chez des animaux intacts, et on s'attend à ce qu'ils soient utiles pour la thérapie génique.
PCT/US1996/012750 1995-08-01 1996-08-01 Enveloppes virales artificielles renforcees pour l'apport de substances therapeutiques dans les cellules WO1997004748A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU66914/96A AU6691496A (en) 1995-08-01 1996-08-01 Enhanced artificial viral envelopes for cellular delivery of therapeutic substances

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US173895P 1995-08-01 1995-08-01
US60/001,738 1995-08-01
US258095P 1995-08-21 1995-08-21
US60/002,580 1995-08-21
US69061396A 1996-07-31 1996-07-31
US60/690,613 1996-07-31

Publications (4)

Publication Number Publication Date
WO1997004748A2 WO1997004748A2 (fr) 1997-02-13
WO1997004748A3 true WO1997004748A3 (fr) 1997-05-29
WO1997004748B1 WO1997004748B1 (fr) 1997-07-17
WO1997004748A9 WO1997004748A9 (fr) 1997-10-09

Family

ID=27356985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/012750 WO1997004748A2 (fr) 1995-08-01 1996-08-01 Enveloppes virales artificielles renforcees pour l'apport de substances therapeutiques dans les cellules

Country Status (2)

Country Link
AU (1) AU6691496A (fr)
WO (1) WO1997004748A2 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335509B2 (en) 1995-01-23 2008-02-26 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8871444B2 (en) 2004-10-08 2014-10-28 Medical Research Council In vitro evolution in microfluidic systems
US9012390B2 (en) 2006-08-07 2015-04-21 Raindance Technologies, Inc. Fluorocarbon emulsion stabilizing surfactants
US9228229B2 (en) 2010-02-12 2016-01-05 Raindance Technologies, Inc. Digital analyte analysis
US9273308B2 (en) 2006-05-11 2016-03-01 Raindance Technologies, Inc. Selection of compartmentalized screening method
US9328344B2 (en) 2006-01-11 2016-05-03 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9448172B2 (en) 2003-03-31 2016-09-20 Medical Research Council Selection by compartmentalised screening
US9498759B2 (en) 2004-10-12 2016-11-22 President And Fellows Of Harvard College Compartmentalized screening by microfluidic control
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039019A1 (fr) * 1996-04-12 1997-10-23 University Of Pittsburgh Nouveaux derives de cholesteryle cationiques contenant des groupes polaires cycliques
US6258792B1 (en) 1996-04-12 2001-07-10 University Of Pittsburgh Cationic cholesteryl derivatives containing cyclic polar groups
FR2751222B1 (fr) 1996-07-16 1998-10-09 Capsulis Compositions contenant au moins un acide nucleique et leurs applications dans le domaine biomedical, en particulier en therapie genique
ES2212305T3 (es) * 1997-06-23 2004-07-16 Alza Corporation Polinucleotidos encapsulados en liposomas, composicion y procedimiento.
ATE278013T1 (de) 1997-07-07 2004-10-15 Medical Res Council In vitro selektionsmethode
FR2766706B1 (fr) * 1997-07-30 2001-05-25 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
FR2766705B1 (fr) * 1997-07-30 2001-05-25 Biovector Therapeutics Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation
US6372720B1 (en) * 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
US6903196B1 (en) 1999-06-17 2005-06-07 Utah Ventures Ii, L.P. Methods for identifying and isolating tissue-specific lumen-exposed molecules
GB0015624D0 (en) * 2000-06-26 2000-08-16 Nat Cancer Centre Materials and methods relating to improved gene delivery
EP1209469A1 (fr) * 2000-11-22 2002-05-29 Vectron Therapeutics AG Production et emploi d'un système diagnostique ciblé
US6713055B2 (en) 2000-11-27 2004-03-30 Geron Corporation Glycosyltransferase vectors for treating cancer
US7622446B2 (en) 2001-04-18 2009-11-24 The Open University Polypeptides, derivatives and uses thereof
US7491702B2 (en) 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
EP2316849A2 (fr) * 2001-04-18 2011-05-04 The Open University Polypeptides comprenant RER, dérivés et leurs utilisations
AU2002256398A2 (en) * 2001-04-30 2002-11-11 Targeted Genetics Corporation Lipid-comprising drug delivery complexes and methods for their production
JP2005501011A (ja) * 2001-06-08 2005-01-13 ユタ ベンチャー ザ セカンド リミテッド パートナーシップ 組織特異的内皮膜タンパク質
WO2004039406A1 (fr) * 2002-11-01 2004-05-13 Genomidea Inc. Preparation medicinale comprenant un agent chimiotherapeutique encapsule
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
EA037929B1 (ru) 2005-03-23 2021-06-08 Генмаб А/С Антитела к cd38 человека и их применение
WO2008097559A2 (fr) 2007-02-06 2008-08-14 Brandeis University Manipulation de fluides et de réactions dans des systèmes microfluidiques
WO2008130623A1 (fr) 2007-04-19 2008-10-30 Brandeis University Manipulation de fluides, composants fluidiques et réactions dans des systèmes microfluidiques
DK2222697T3 (da) 2007-11-01 2013-03-11 Perseid Therapeutics Llc Immunsuppressive polypeptider og nukleinsyrer
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
EP2315629B1 (fr) 2008-07-18 2021-12-15 Bio-Rad Laboratories, Inc. Bibliothèque de gouttelettes
WO2010111231A1 (fr) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation de gouttelettes microfluidiques
EP2486409A1 (fr) 2009-10-09 2012-08-15 Universite De Strasbourg Nanomatériau marqué à base de silice à propriétés améliorées et ses utilisations
WO2011079176A2 (fr) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Systèmes microfluidiques et procédés pour réduire l'échange de molécules entre des gouttelettes
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
EP3412778A1 (fr) 2011-02-11 2018-12-12 Raindance Technologies, Inc. Procédés permettant de former des gouttelettes mélangées
WO2012112804A1 (fr) 2011-02-18 2012-08-23 Raindance Technoligies, Inc. Compositions et méthodes de marquage moléculaire
EP3709018A1 (fr) 2011-06-02 2020-09-16 Bio-Rad Laboratories, Inc. Appareil microfluidique pour l'identification de composants d'une reaction chimique
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
US9340784B2 (en) * 2012-03-19 2016-05-17 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
CA3099497A1 (fr) * 2018-05-15 2019-11-21 Flagship Pioneering Innovations V, Inc. Compositions de fusosome et leurs utilisations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475178A1 (fr) * 1990-08-27 1992-03-18 Kabushiki Kaisha Vitamin Kenkyusyo Liposome pour envelopper un gène, préparation liposomale et procédé de manufacture de la préparation
EP0497997A1 (fr) * 1991-02-02 1992-08-12 Nika Health Products Limited Vésicules membranaires synthétiques contenant des peptides de fusion fonctionellement actifs comme systèmes de délivrance d'un médicament
EP0544292A2 (fr) * 1991-11-27 1993-06-02 Roche Diagnostics GmbH Méthode d'introduction d'acides nucléiques dans des cellules
WO1994018947A1 (fr) * 1993-02-16 1994-09-01 Sharifa Karali Complexe protamine-adn de haute purete et son utilisation
WO1996040964A2 (fr) * 1995-06-07 1996-12-19 Inex Pharmaceuticals Corporation Particules d'acides nucleiques et de lipides preparees au moyen d'un intermediaire de complexe hydrophobe d'acides nucleiques et de lipides et utilisation pour transferer des genes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475178A1 (fr) * 1990-08-27 1992-03-18 Kabushiki Kaisha Vitamin Kenkyusyo Liposome pour envelopper un gène, préparation liposomale et procédé de manufacture de la préparation
EP0497997A1 (fr) * 1991-02-02 1992-08-12 Nika Health Products Limited Vésicules membranaires synthétiques contenant des peptides de fusion fonctionellement actifs comme systèmes de délivrance d'un médicament
EP0544292A2 (fr) * 1991-11-27 1993-06-02 Roche Diagnostics GmbH Méthode d'introduction d'acides nucléiques dans des cellules
WO1994018947A1 (fr) * 1993-02-16 1994-09-01 Sharifa Karali Complexe protamine-adn de haute purete et son utilisation
WO1996040964A2 (fr) * 1995-06-07 1996-12-19 Inex Pharmaceuticals Corporation Particules d'acides nucleiques et de lipides preparees au moyen d'un intermediaire de complexe hydrophobe d'acides nucleiques et de lipides et utilisation pour transferer des genes

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7335509B2 (en) 1995-01-23 2008-02-26 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US7361640B2 (en) 1995-01-23 2008-04-22 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US9448172B2 (en) 2003-03-31 2016-09-20 Medical Research Council Selection by compartmentalised screening
US8871444B2 (en) 2004-10-08 2014-10-28 Medical Research Council In vitro evolution in microfluidic systems
US9186643B2 (en) 2004-10-08 2015-11-17 Medical Research Council In vitro evolution in microfluidic systems
US9498759B2 (en) 2004-10-12 2016-11-22 President And Fellows Of Harvard College Compartmentalized screening by microfluidic control
US9328344B2 (en) 2006-01-11 2016-05-03 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
US9410151B2 (en) 2006-01-11 2016-08-09 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
US9534216B2 (en) 2006-01-11 2017-01-03 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
US9273308B2 (en) 2006-05-11 2016-03-01 Raindance Technologies, Inc. Selection of compartmentalized screening method
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
US9012390B2 (en) 2006-08-07 2015-04-21 Raindance Technologies, Inc. Fluorocarbon emulsion stabilizing surfactants
US9498761B2 (en) 2006-08-07 2016-11-22 Raindance Technologies, Inc. Fluorocarbon emulsion stabilizing surfactants
US9228229B2 (en) 2010-02-12 2016-01-05 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing

Also Published As

Publication number Publication date
AU6691496A (en) 1997-02-26
WO1997004748A2 (fr) 1997-02-13

Similar Documents

Publication Publication Date Title
WO1997004748A3 (fr) Enveloppes virales artificielles renforcees pour l'apport de substances therapeutiques dans les cellules
WO1997004748B1 (fr) Enveloppes virales artificielles renforcees pour l'apport de substances therapeutiques dans les cellules
WO1998051278A3 (fr) Encapsulation hautement efficace d'agents therapeutiques charges dans des vesicules lipidiques
CA2154445A1 (fr) Ciblage lysosomal d'immunogenes
CA2182303A1 (fr) Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire
WO1998004242A3 (fr) Vecteurs de liberation d'une substance dans des tumeurs et procede pour renforcer le traitement de tumeurs kystiques
UA42089C2 (uk) Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
AU7599500A (en) Novel gl50 molecules and uses therefor
BR0316402A (pt) vesìcula fusogênica, métodos para preparar uma vesìcula fusogênica encapsulante, e para encapsular pelo menos uma substáncia terapêutica ou imunologicamente ativa em uma vesìcula fusogênica, uso de uma vesìcula fusogênica, e, formulação farmacêutica
AU4283596A (en) Yeast-based delivery vehicles
EP1798239A3 (fr) Récepteurs de protéine G-couplés et utilisations correspondantes
CA2285056A1 (fr) Methode pour l'introduction de substances pharmaceutiques et d'acides nucleiques dans le muscle squelettique
CN1140989A (zh) 具有控制释放活性成分作用的囊
WO2001049324A3 (fr) Nouveaux vecteurs synthetiques colloides destines a la therapie genique
PL362804A1 (en) Novel b7-4 molecules and uses therefor
Lopes et al. Liposome‐mediated delivery stimulates a class I‐restricted cytotoxic T cell response to soluble antigen
AU716500B2 (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
WO1995019435A3 (fr) Proteines de la region v du recepteur d'antigene des lymphocytes t et leurs procedes de preparation
NZ322910A (en) Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
CN1915968A (zh) 用于核酸及药物传递的中性－阳离子类脂
Frisch et al. Parameters affecting the immunogenicity of a liposome‐associated synthetic hexapeptide antigen
IL134593A0 (en) A cell system for in-vivo expression of an interferon beta protein, pharmaceutical compositions containing the same and methods for the preparation thereof
IL128735A0 (en) Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
WO1998027966A3 (fr) Cellules encapsulees productrices d'anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US US US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 9,10,59,74 AND 76,DESCRIPTION,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;PAGES 1/18-18/18,DRAWINGS,REPLACED BY NEW PAGES 1/20-20/20;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载